VEMLIDY (TENOFOVIR ALAFENAMIDE) FOR CHRONIC HEPATITIS B

  • Abimbola Farinde Columbia Southern University, Orange Beach, Alabama, United States

Abstract

Hepatitis was once viewed as a rampant and incurable disease but within recent years therapies have been released that offer hope and the improvement in quality of life through symptoms control. The purpose of this manuscript is to discuss the use of VEMLIDY as a new treatment for hepatitis B and examine its use among the current therapies that are on the market. VEMLIDY offers another therapeutic option for patients currently diagnosed with this Hepatitis B and for those who may have failed therapy with other agents.

Published
Jul 31, 2017
How to Cite
FARINDE, Abimbola. VEMLIDY (TENOFOVIR ALAFENAMIDE) FOR CHRONIC HEPATITIS B. International Journal of Drug Research and Technology, [S.l.], v. 7, n. 4, p. 13, july 2017. ISSN 2277-1506. Available at: <http://ijdrt.com/index.php/drug-research-and-technology/article/view/129>. Date accessed: 17 aug. 2017.
Section
Research Article